Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionomics Limited stock logo
BNOEF
Bionomics
$0.00
-43.3%
$0.00
$0.00
$0.06
$4.45M1.86140,299 shs22,900 shs
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$5.51
$4.00
$6.92
$200.47M2.16189,500 shs64,100 shs
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$0.22
$0.22
$0.08
$0.34
$56.90M2.65,474 shsN/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionomics Limited stock logo
BNOEF
Bionomics
0.00%0.00%0.00%0.00%0.00%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.00%0.00%0.00%0.00%0.00%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/AN/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bionomics Limited stock logo
BNOEF
Bionomics
0.00
N/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.00
N/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$10.72M0.00N/A23.28$3.63 per share0.00
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$7.38M7.71N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/A0.00N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
-$18.79M-$0.08N/AN/A-254.66%-346.72%-94.54%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bionomics Limited stock logo
BNOEF
Bionomics
N/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.14
10.10
10.10
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.64
1.35
0.90

Institutional Ownership

CompanyInstitutional Ownership
Bionomics Limited stock logo
BNOEF
Bionomics
N/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
19.39%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.02%

Insider Ownership

CompanyInsider Ownership
Bionomics Limited stock logo
BNOEF
Bionomics
N/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
1.10%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bionomics Limited stock logo
BNOEF
Bionomics
N/A1.31 billionN/ANot Optionable
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
2234.51 million34.13 millionOptionable
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
29258.62 millionN/ANot Optionable

Recent News About These Companies

Takeda Pharmaceutical Co. Ltd. ADR
Other OTC Pharmaceuticals - Lithuania
Acerus Reports Second Quarter 2022 Financial Results
Bionomics stock logo

Bionomics OTCMKTS:BNOEF

$0.0034 0.00 (-43.33%)
As of 09/19/2023

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:KMPH

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Acerus Pharmaceuticals stock logo

Acerus Pharmaceuticals OTCMKTS:TRLPF

$0.22 0.00 (0.00%)
As of 07/21/2023

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.